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Objectives The purpose of this study was to examine smoking cessation rates among smokers with AMI to determine
whether bupropion, started in-hospital, is safe and can improve cessation rates at 1 year.
Background Bupropion doubles quit rates in otherwise healthy smokers and patients with stable cardiovascular disease. Al-
though 2 previous trials examined the use of bupropion in patients hospitalized with acute cardiovascular dis-
ease, these studies have been inconclusive with respect to its safety and efficacy in patients with acute myocar-
dial infarction (AMI).
Methods We conducted a multicenter, double-blind, placebo-controlled, randomized trial in smokers hospitalized with
AMI. Participants received bupropion or placebo for 9 weeks and were followed for 12 months. Both groups re-
ceived low-intensity counseling. Point prevalence abstinence was assessed by 7-day recall and biochemical vali-
dation of expired carbon monoxide.
Results A total of 392 patients were randomized (mean age 53.9  10.3 years); 83.5% were male; 64.9% had ST-
segment elevation myocardial infarction). Patients smoked a mean of 23.2  10.6 cigarettes/day for a mean of
32.9  12.4 years. At 12 months, point prevalence abstinence rates were 37.2% in the bupropion group and
32.0% in the placebo group (p  0.33; % difference after adjusting for between center differences 3.9%). Con-
tinuous abstinence rates were 26.8% and 22.2%, respectively (p  0.34). Major adverse cardiac event rates
were similar (13.0% vs. 11.0%, respectively; p  0.64).
Conclusions Two-thirds of patients return to smoking by 12 months after AMI. Bupropion is well tolerated and seems to
be safe to use in the immediate post-AMI period. However, bupropion is not effective for smoking cessation
in patients post-AMI. (Zyban as an Effective Smoking Cessation Aid for Patients Following an Acute Coro-
nary Syndrome: The ZESCA Trial; NCT00689611) (J Am Coll Cardiol 2013;61:524–32) © 2013 by the
American College of Cardiology Foundation
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February 5, 2013:524–32 Bupropion for Smoking Cessation in Patients With AMIBecause persistent smoking after acute myocardial infarction
(AMI) is associated with a greatly increased risk of reinfarction
(1) and death (2–4), immediate and sustained smoking
essation is a major therapeutic goal in the treatment of
hese patients. Multiple clinical trials and meta-analyses
ave shown that both nicotine replacement therapies and
on-nicotine replacement therapies are effective for smok-
ng cessation in otherwise healthy smokers without coronary
rtery disease (5–7). Although 2 previous trials examined the use
f bupropion in patients hospitalized with acute cardiovascular
isease, these studies have been inconclusive with respect to its
afety and efficacy in patients with AMI (8,9). Patients with AMI
ay be more motivated to quit than patients examined in earlier
tudies; at the same time, their long-standing nicotine addiction
ay make them less likely to respond to smoking cessation
See page 533
therapies. Although nicotine replacement therapies are prescribed
in-hospital by many North American physicians, there is a lack of
randomized evidence to support their safety in the early period
after a myocardial infarction (10,11). In addition, 2 recent studies
have presented conflicting results regarding a possible increase in
the incidence of cardiovascular events with the use of varenicline
(12,13).
Bupropion is an antidepressant whose efficacy in smoking
cessation is thought to result from its inhibitory action on
the neuronal reuptake of dopamine and norepinephrine, as
well as on the nicotinic acetylcholine receptors (10). Bupro-
pion suppresses nicotine withdrawal symptoms, but unlike
nicotine replacement therapies, it has little effect on heart
rate and blood pressure (14). The antidepressant effects of
bupropion may have particular benefit in the post-AMI
setting. Although caution is advised with the use of nicotine
replacement therapies during the 2-week period immedi-
ately after an AMI (10), a 2008 clinical practice guideline
issued by the U.S. Department of Health and Human
Services suggests that bupropion can be safely used during
this period (10). Bupropion approximately doubles quit
rates in otherwise healthy smokers and patients with stable
cardiovascular disease (5,7), but its efficacy and safety in
patients hospitalized with AMI is unknown. For this
reason, we performed a randomized placebo-controlled trial
in smokers hospitalized with AMI. Our goals were to
examine smoking cessation rates among smokers with AMI
and to determine whether bupropion, begun in-hospital, is
safe and can improve cessation rates at 1 year.
Methods
Study design and patient population. The ZESCA
(Zyban as an Effective Smoking Cessation Aid for Patients
Following an Acute Coronary Syndrome) trial (NCT00689611)
was a multicenter, double-blind, randomized, placebo-controlled
trial that examined the efficacy and safety of bupropion for
smoking cessation in patients with AMI (Online Table 1). A totalof 392 patients who smoked at least
10 cigarettes per day and who were
hospitalized with an enzyme-
positive AMI were enrolled (Fig. 1).
Eligible, consenting patients who
met the inclusion and exclusion cri-
teria (Online Table 2) were ran-
domized at least 24 h before dis-
charge in a 1:1 ratio to receive bupropion sustained-release or
placebo. Randomization was done via an internet website using
random blocks of 2 and 4 and was stratified by center to ensure
that similar numbers of patients were randomized to the 2 arms of
the study at each study center. Each center received ethics approval
from their research ethics board before the start of the trial.
Baseline assessment, intervention, and follow-up. After
randomization, a baseline questionnaire was used to docu-
ment demographic, smoking, and clinical characteristics of
patients. In addition, nicotine dependence and severity of
depressive symptoms were measured using the Fagerström
Test for Nicotine Dependence (15) and the Beck Depres-
sion Inventory II (16), respectively.
The behavioral counseling provided in the trial consisted
of minimal clinical intervention that included brief advice to
“stop smoking” and the importance of smoking cessation
post-MI. This intervention was administered in-hospital by
the attending physician before randomization and was
approximately 2 min in length. Additional counseling was
received at baseline (post-randomization) and at all follow-
ups (both telephone and clinic visits). The sessions consisted
of brief advice delivered in 20 min (average of 5 min) to
“stop smoking” and was based on the “5 A’s” model: 1) Ask
about smoking; 2) Advise all smokers to quit; 3) Address
willingness to quit; 4) Assist patients who want to quit;
and 5) Arrange follow-up visits. The counseling con-
sisted of a discussion of withdrawal symptoms, triggers
for relapse, and strategies and motivation to help patients
remain abstinent or strategies to achieve abstinence in
patients who relapsed (Online Tables 3 and 4). Counsel-
ing was administered to all patients by the research nurses
at baseline and follow-up visits. In addition to the
counseling provided by the research nurses, patients were
allowed to receive supplementary counseling if their site
had a smoking cessation clinic.
Patients received their first dose of study medication
within 24 h of randomization and while they were still
in-hospital. Bupropion was administered as 150 mg daily
for 3 days, followed by 150 mg twice daily for the remainder
of the 9-week treatment period. Patients in the placebo
group received a matching placebo administered with the
same schedule. Patients stopped smoking at the time of
hospital admission. At the time of randomization, they were
instructed not to resume smoking. During the 9-week
treatment period, patients experiencing intractable insomnia
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CO  carbon monoxide
ITT  intention-to-treatwere allowed to reduce their study medication to 1 pill every
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of Health Research and by the Heart and Stroke Founda-
tion of Quebec. No industry support was received, either
financial or in the form of study medication. Bupropion and
identical placebo tablets were purchased from Sandoz Can-
ada Inc. (Boucherville, Quebec, Canada). An independent
industrial pharmacist was responsible for coating, bottling,
and packaging the medication for distribution to collabo-
rating sites.
Follow-up consisted of weekly phone calls by research
nurses at weeks 1 and 2, as well as clinic visits at weeks 4 and
9, and months 6 and 12 (Online Fig. 1). Phone calls were
used to assess side effects and withdrawal symptoms. In
addition, patients were asked if they had smoked in the past
week and whether they were taking their study medication.
During clinic visits, smoking status and clinical events were
assessed. Smoking status assessment consisted of a self-
report of smoking in the previous 7 days and biochemical
validation by measurement of exhaled carbon monoxide
(CO) levels. A threshold of exhaled CO 10 ppm on a CO
monitor (Micro 4 Smokerlyzer, Bedfont Scientific Ltd.,
Rochester, United Kingdom) was used to confirm smoking
abstinence (17).
Screening logs were not mandatory in this trial. Never-
theless, screening logs were forwarded to us from 15 of the
38 collaborating sites. From the logs of these 15 sites, 1,081
patients were screened to identify 778 current smokers (10
cigarettes/day). Of the 778 smokers, 584 were excluded for
various reasons (e.g., did not meet myocardial infarction
Figure 1 Randomization and Follow-Up of Study Patients
*Two patients who withdrew consent did not receive treatment. †One patient w
who died. For the ITT analysis, patients who were lost to follow-up or withdrew
patients enrolled, 3.8% died and 22.2% were lost to follow-up. Among those lo
Vital status was obtained for 10 patients in the bupropion group and 9 patient
ITT  intention-to-treat; SR  sustained-release.definition [39.6%], history or current diagnosis of a psychi-atric disorder [10.6%], renal failure/impairment [5.0%],
history of seizure or use of medication that lowers seizure
threshold [4.1%], use of illegal drugs [4.5%], excessive
alcohol use [3.1%], hepatic failure [2.7%], currently using a
pharmacotherapy for smoking cessation [1.7%], not moti-
vated to quit smoking [1.3%], participating in another study
[1.4%], patient discharged [1.2%], too ill to participate
[0.7%], recently underwent surgery [0.7%], physician re-
fused [0.2%], and various other exclusion criteria [22.8%]),
leaving a total of 194 eligible patients. Of the 194 eligible
patients, 129 (18.1%) declined to participate. Thus, one
third of the eligible smokers at these sites were enrolled in
the trial.
Endpoint assessment. The primary end point was point
prevalence smoking cessation at 12 months. Smoking ces-
sation was defined as complete abstinence in the week
before the 12-month clinic visit (documented by self-report)
and a measurement of exhaled CO 10 ppm. Smoking
cessation also was assessed at 4 weeks, 9 weeks, and 6
months. In addition to point prevalence smoking cessation,
we also examined continuous abstinence (defined as nega-
tive self-report and CO 10 ppm at all follow-up periods)
and the number of cigarettes smoked/day as secondary
measures of smoking status. Secondary end points included
the safety and tolerability of bupropion, based on the
incidence of clinical events and nondangerous side effects.
All clinical end points were adjudicated by members of the
Endpoints Evaluation Committee who were blinded to
treatment assignment (Online Table 5). An external Data
thdrew consent did not receive treatment. ‡Includes all patients except those
assumed to have gone back to smoking at baseline rates. §Of the 392
ollow-up, vital status was obtained via medical charts for 8.7% of patients.
e placebo group among those who did not return for clinical follow-up.ho wi
were
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s in thand Safety Monitoring Board monitored the trial. An
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enrollment and was repeated annually.
Data analysis. The initial descriptive analysis examined
the balance of demographic, smoking, and clinical char-
acteristics between the 2 treatment groups. Characteris-
tics of the hospital course also were examined. Descrip-
tive statistics were examined using medians, interquartile
ranges, means, standard deviations (SDs), and percent-
ages as appropriate, both overall and within treatment
groups.
The primary data analysis examined smoking cessation
rates at 4 and 9 weeks, and 6 and 12 months, with the
primary end point being point prevalence smoking cessation
at 12 months. The primary end point was analyzed as
differences in cessation rates between bupropion and
placebo groups with corresponding p values calculated
using a Fisher exact test. The primary end point was
analyzed on an intention-to-treat (ITT) basis. Because
loss to follow-up rates 30% are not unusual in smoking
cessation trials (8,18), our ITT analysis assumed that
those who withdrew consent or were lost to follow-up
had returned to smoking at their baseline rates. This
assumption is common in smoking cessation trials, be-
cause 75% of patients return to smoking at 1 year in
most trials even while receiving active pharmacotherapy.
In addition to our ITT analyses, we also performed per
protocol analyses that involved only patients who re-
turned for follow-up visits.
Secondary data analyses examined serious adverse events,
side effects, and medication compliance and were also
calculated as differences between the 2 groups. Serious
adverse events and nonharmful side effects were compared
in the 2 treatment groups at weeks 1, 2, 4, and 9 and months
6 and 12 (cumulative events at 9 weeks being the primary
measure for side effects). For safety analyses, patients who
withdrew from the study, were lost to follow-up, or died
were accounted for by censoring at the time of death or at
the last follow-up contact. Statistical analyses were per-
formed using SAS statistical software version 9.2 (SAS
Institute Inc., Cary, North Carolina).
Results
Baseline characteristics. Baseline demographic, smoking,
and clinical characteristics were well balanced among pa-
tients in the 2 arms of the trial (Table 1). The only
imbalance noted was a history of diabetes. Approximately
two thirds of patients were enrolled at North American
sites, and most patients were middle-aged men who had
smoked for 3 decades. Patients smoked approximately 1
pack/day, two thirds reported at least 1 prior attempt to quit
smoking, and one third reported living with other smokers.
One third of all patients had previously used a nicotine
replacement therapy or a non-nicotine replacement therapy
in an attempt to quit smoking. The scores on the Fager-
ström Test for Nicotine Dependence ranged between 0 and m10, with 82.2% of patients having moderate or severe
nicotine dependence (scores 4) (15). The scores on the
Beck Depression Inventory II ranged between 0 and 63,
with 19.9% having scores consistent with depressive symp-
tomatology (scores 14) (16).
Hospital course. Characteristics of the hospital course
also were well balanced between the 2 arms of the trial
(Table 1). Approximately two thirds of patients presented
with an ST-segment elevation myocardial infarction.
Although all patients enrolled in the trial had positive
cardiac enzymes (creatine kinase-myocardial band frac-
tion, troponin I, or troponin T), more than three quarters
had an enzyme elevation 3 times the upper limit of
normal for their hospital. More than two thirds of
patients had a coronary angiogram during the hospital
admission, and more than half of patients underwent
percutaneous coronary intervention or coronary artery
bypass grafting. There were relatively few cases of con-
gestive heart failure, recurrent ischemia, or ventricular
arrhythmias. Median length of hospital stay was 4.0 days,
and median time from admission to first dose of study
medication was 2.0 days. Discharge medications (other
than study medication) were similar in both groups.
Smoking cessation. Over the course of the trial, there was
a progressive decline in smoking cessation rates so that by 12
months, two thirds of patients had returned to smoking
(Fig. 2A). Although there were higher rates of smoking
cessation among patients taking bupropion at 4 weeks, 9
weeks, 6 months, and 12 months, these differences did not
achieve statistical significance. For the primary end point of
smoking abstinence at 12 months, rates were 37.2% and
32.0%, respectively (p  0.33). A secondary analysis, ad-
justing for between center differences showed an absolute
difference between groups of 3.9%. Per protocol analyses
showed similar results.
In addition to point prevalence abstinence, we also
performed an ITT analysis of continuous smoking ces-
sation (Fig. 2B). These results parallel those of the point
prevalence analysis, but further showed that 25% of
patients were consistently abstinent during the 12-month
follow-up with no statistically significant difference be-
tween groups.
Although two-thirds of patients with AMI returned to
smoking by 12 months, many of these patients substantially
reduced their daily cigarette consumption (Fig. 3). ITT
analysis showed that among persistent smokers, there was a
reduction in mean daily cigarette consumption from 23.2 
0.6 at baseline to 8.4  11.3 at 12 months. Among
patients who returned for follow-up at 12 months, cigarette
consumption decreased from a mean of 22.8  10.5 at
baseline to 4.7  7.3 at 12 months, with no difference
etween bupropion and placebo groups.
ounseling. The mean duration of counseling adminis-
ered to patients over the course of the trial was 45.0 24.3
in. The average time per counseling session was 6.4  3.5
in. If patients relapsed, their treating physicians were
528 Eisenberg et al. JACC Vol. 61, No. 5, 2013
Bupropion for Smoking Cessation in Patients With AMI February 5, 2013:524–32allowed to prescribe any type of open-label pharmacother-
apy for smoking cessation.
Study drug adherence, adverse events, and side effects. By
the end of the 9-week treatment period, 72.3% of
patients randomized to the bupropion group were taking
at least 1 pill of study medication per day versus 82.0%
Characteristics of Smokers With AMI According to TreatTable 1 Characteristics of Smokers With AMI Accord
Demographic
Age (yrs)
Male (%)
Smoking
No. of years smoked
No. of cigarettes/day (past year)
Prior attempt to quit smoking (%)
Previous serious quit attempts (%)
0
1
2
 3
Other smokers at home (%)
Prior use of abstinence aids (%)
Nicotine replacement therapy†
Bupropion
Counseling
Other
Fagerstrom test for Nicotine Dependence score (%)‡
0 to 3 (mild)
4 to 6 (moderate)
7 (severe)
Clinical
Medical history (%)
Hyperlipidemia
Hypertension
Diabetes
Prior use of antidepressants
Prior MI
Prior PCI
Prior CABG
Prior TIA or CVA
Beck Depression Inventory-II score (%)§
14
Hospitalization
STEMI (%)
NSTEMI (%)
Procedures (%)
Cardiac catheterization
PCI
CABG
Complications (%)
CHF
Recurrent ischemia
Ventricular arrhythmia
LVEF (%)
Length of stay (days)¶
Time from admission to first dose of study medication (days)¶among patients randomized to the placebo group (p 0.05) (drug adherence data available for 230 patients).
Serious adverse events were rare, and their occurrence was
well balanced between the 2 arms of the trial (Table 2). Rates
of neurologic or psychiatric events were low. A number of
side effects were common during the 9-week treatment
period, but no statistically significant differences were
Group*o Treatment Group*
pion (n  192) Placebo (n  200) All Patients (n  392)
4.5  10.4 53.4  10.3 53.9  10.3
83.8 83.2 83.5
3.2  13.0 32.6  11.9 32.9  12.4
3.2  10.8 23.2  10.4 23.2  10.6
68.8 66.0 67.3
29.7 33.0 31.3
31.2 19.5 25.3
14.6 20.5 17.6
24.5 27.0 25.8
33.3 38.4 35.9
34.9 31.3 33.1
30.2 28.0 29.1
8.4 7.6 8.0
1.0 1.0 1.0
5.2 3.0 4.1
18.4 17.2 17.8
46.3 44.4 45.3
35.3 38.4 36.9
51.6 47.5 49.5
42.1 36.9 39.4
22.6 11.6 17.0
8.4 7.6 8.0
19.5 22.2 20.9
10.5 10.1 10.3
3.2 2.5 2.8
2.6 1.0 1.8
19.8 20.0 19.9
63.2 66.7 64.9
36.8 33.3 35.1
66.8 68.2 67.5
48.4 52.0 50.3
5.3 7.6 6.4
5.8 3.0 4.4
3.7 4.5 4.1
7.9 8.6 8.2
8.6  10.7 49.6  10.9 49.1  10.8
4.0 (3–6) 4.0 (3–6) 4.0 (3–6)
2.0 (1–3) 2.0 (1–3) 2.0 (1–3)
Continued on the next pagementing t
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smoking cessation beyond the treatment medication dur-
ing the 12-month period.
Discussion
Our study was designed to examine cessation rates among
smokers with AMI and to determine whether bupropion,
begun in-hospital, is safe and can improve cessation rates at
1 year. We found that two thirds of patients return to
smoking by 12 months after AMI. We also found that
bupropion is well tolerated and seems to be safe in the
immediate post-AMI period. However, bupropion is not
effective for smoking cessation in patients post-AMI. These
results suggest that smoking remains a major issue in the
patient population with AMI. These patients have smoked,
on average, for 3 decades, and despite having a major
cardiac event related to smoking, they still have serious
difficulty quitting.
Previous studies. To our knowledge, there have been no
previous trials of pharmacotherapy for smoking cessation
performed exclusively in a population with AMI. Many pre-
vious studies have demonstrated that both behavioral therapy
and pharmacotherapy are effective for smoking cessation in
otherwise healthy smokers without coronary artery disease
(5,6). However, there have only been a limited number of trials
examining the use of pharmacotherapies in patients with
cardiovascular disease (19).
Three previous trials examined the use of bupropion in
heterogeneous populations of patients with a variety of
cardiovascular conditions. Unfortunately, none of these
ContinuedTable 1 Continued
Bupropion (n  19
Time of discharge
Medications at discharge (%)#
ACE inhibitor 72.4
Angiotensin receptor blocker 6.3
Anti-arrhythmia agent 2.6
Aspirin 95.8
Beta blocker 85.4
Calcium channel blocker 7.8
Clopidogrel 63.5
Insulin 3.1
Lipid-lowering agent 83.9
Nitrate 30.7
Oral hypoglycemic drug 16.1
Sublingual nitroglycerin 51.6
Warfarin 9.4
Values are mean  SD, %, or median (interquartile range). *4 patients, 2 in ea
inhaler, and patch. ‡Score ranges between 0 and 10. §A 21-scale itemwith ran
were available for 257 patients. ¶Median (interquartile range). #Medications a
200 in the placebo group.
ACE  angiotensin-converting enzyme; CABG  coronary artery bypass g
ventricular ejection fraction; MI  myocardial infarction; NSTEMI  non–ST-s
STEMI  ST-segment elevation myocardial infarction; TIA  transient ischemstudies reported cessation rates in their AMI subgroups. tTonstad et al. (7) randomized 626 patients (including
307 with AMI 3 months previously) and found that
smoking cessation rates at 12 months were 27% in the
bupropion group and 12% in the placebo group (p 
0.05). Rigotti et al. (8) randomized 247 patients with
acute cardiovascular disease (including 121 hospitalized
with AMI) and found cessation rates of 25.0% and 21.3%
(p  NS) at 12 months. The study by Rigotti et al. (8)
sed high-intensity behavioral counseling in addition to
upropion. Planer et al. (9) randomized 151 patients
including 60 hospitalized with AMI) and found cessa-
ion rates of 31% and 33% at 1 year (p  NS). Nicotine
atch and nicotine gum were each examined in individual
rials involving a variety of cardiovascular conditions, but
hese trials had disappointing results. Varenicline has
een shown to have a benefit in outpatients with stable
ardiovascular conditions (20). However, 2 studies have
resented conflicting results regarding a possible in-
reased incidence of cardiovascular events with the use of
arenicline (12,13). Aside from our study, no trials have
pecifically focused on patients hospitalized with AMI, a
atient population who are at high risk for recurrent
ardiac events and in whom smoking cessation is of
rucial importance.
Our study suggests that patients hospitalized with
MI may be more highly motivated to quit smoking than
ealthy smokers without coronary artery disease or pa-
ients with stable cardiovascular disease. Among the
atients in the control arm of our trial, 47% were
bstinent at 4 weeks and 32% were abstinent at 12
onths. These results are better than those reported in
Placebo (n  200) All Patients (n  392)
68.0 70.2
4.0 5.1
4.5 3.6
93.5 94.6
84.0 84.7
8.0 7.9
66.0 64.8
6.0 4.6
84.0 83.9
27.5 29.1
8.0 12.0
49.5 50.5
9.0 9.2
tment group, did not have baseline data reported. †Comprises nicotine gum,
0 to 63. A score of14 is reflective of depressive symptomatology (16). Data
arge reported for N  391 patients: N  191 in the bupropion group and N 
F  congestive heart failure; CVA  cerebrovascular accident; LVEF  left
t elevation myocardial infarction; PCI  percutaneous coronary intervention;
k.2)
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diovascular disease and suggest that patients with AMI
are more highly motivated to quit.
The “teachable” moment presented by a smoking-related
hospital admission for AMI is thought to be an opportune
time to encourage patients to quit smoking (10). In addition
to our study, several observational studies have documented
high initial quit rates after an AMI only to be followed by
high relapse rates. Compared with smokers enrolled in
previous smoking cessation trials, most patients with AMI
are older and have been smoking for many decades. Despite
their motivation to quit, their long-standing nicotine addic-
tion may make them less responsive to smoking cessation
Figure 2 Smoking Cessation by
Treatment Group (ITT Analysis)
Patients who withdrew consent or were lost to follow-up were considered to
have returned to smoking. Patient numbers were as follows: at 4 weeks in the
bupropion (N  188) and placebo (N  200) groups; at 9 weeks in the bupro-
pion (N  188) and placebo (N  198) groups; at 6 months in the bupropion
(N  185) and placebo (N  195) groups; and at 12 months in the bupropion
(N  183) and placebo (N  194) groups. (A) Point prevalence abstinence.
Patients were considered abstinent if they abstained from smoking in the 7
days before the visit through a self-report of 0 cigarettes smoked/day, con-
firmed by a CO monitor reading 10 ppm. (B) Continuous abstinence. Patients
were considered abstinent if they abstained from smoking through a self-report
of 0 cigarettes smoked/day, confirmed by a CO monitor reading 10 ppm at
all follow-up periods. ITT  intention-to-treat.therapies.We observed that many persistent smokers reduced their
daily cigarette consumption from approximately 1 pack/day
at baseline to less than 10 cigarettes/day at 12 months.
Although some studies suggest that reducing consumption
does not affect disease risk (21), the INTERHEART study
group found a linear relationship between the number of
cigarettes smoked/day and the risk of a de novo AMI (22).
ven if reduced consumption does not reduce disease risk, it
ndicates a subset of patients who could be retargeted for
moking cessation interventions.
tudy limitations. Several potential limitations of our
tudy should be noted. First, our study recruited only
atients with AMI who were willing to attempt to quit
moking. A large number of patients were approached for
nclusion in this study who were unwilling to even consider
uitting. For this reason, the quit rates reported in our study
re likely higher than those that would be observed in the
MI population at large. Second, similar to other smoking
essation trials, a not insubstantial number of patients
ithdrew from our study or were lost to follow-up. Previous
moking cessation trials have reported dropout rates 30%.
mong the 377 surviving patients in our study, 22.2%
ithdrew consent or were lost to follow-up. These results
re better than those observed in previous trials and are
ikely due to the higher level of motivation among patients
ith AMI. Third, our study included a low-intensity
ehavioral counseling intervention and similar to the study
y Planer et al. (9) found no effect of bupropion. However,
he study by Rigotti et al. (8) administered high-intensity
ehavioral counseling intervention in addition to bupropion
herapy and found similar results. Finally, because of the
Figure 3 Mean Daily Cigarette Consumption
by Treatment Group (ITT Analysis)
Nonsmokers were excluded from this analysis. Patients who were lost to fol-
low-up or withdrew were considered to have returned to smoking at baseline
rates. Patient numbers were as follows: at baseline in the bupropion (N 
190) and placebo (N  198) groups; at 4 weeks in the bupropion (N  186)
and placebo (N  198) groups; at 9 weeks in the bupropion (N  186) and
placebo (N  196) groups; at 6 months in the bupropion (N  183) and pla-
cebo (N  193) groups; and at 12 months in the bupropion (N  181) and
placebo (N  192) groups. ITT  intention-to-treat.
n; SAE
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occurred, we had limited power to examine our secondary
safety end points.
Conclusions
Our study was designed to examine smoking cessation rates
among smokers with AMI and to determine whether
bupropion, started in-hospital, is safe and can improve
cessation rates at 1 year. We found that two thirds of
patients return to smoking by 1 year after AMI. We also
found that bupropion is well tolerated and seems to be safe
to use in the immediate post-AMI period. However, bu-
propion is not effective for smoking cessation in patients
post-AMI.
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treatment period. In the bupropion group, a patient died 2 days p
cardiac arrest 5 days post-randomization. A third patient died 9 days
patient died 4 weeks post-randomization of a myocardial infarction
the time of the event. In the placebo group, a patient died of complic
post-randomization. A second patient died of an ischemic event in
event could not be ruled out due to a recent infarct with occlusio
medication at the time of the event. All events were deemed to n
suicidal ideation. §Includes abdominal pain, abscess, atelectasis, at
obstructive pulmonary disease, congestive heart failure, dorsal
thrombosis, laminectomy, major bleed post-percutaneous coronary
endarterectomy. Cumulative sum of side effects reported throug
telephone visits.
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